莆田附近聊天的妇女-莆田附近聊天的妇女_主页

在临沧酒店晚上怎么叫服务

Welcome to the official website of Yantai Dongcheng Pharmaceutical Group Co., Ltd!
Stock Code: 002675
development history
Your current position: home page >> About Dongcheng >>Development history

 

 

 

 

In 2019

In December, the seminar on children's 13C accurate detection held successfully, which opened a new era of HP detection for children in China.

In December, the company signed a cooperation agreement on PET imaging diagnosis of Parkinson's disease with South Korea's DCB company.

In September, the cooperation project of HP Detection Center & 125I particle center jointly built by the company and Shanghai Pharmaceutical Holdings Co., Ltd. was successfully signed, and the new mode of product operation was innovated.

In September, the company signed a strategic cooperation agreement on 13C project with Israel Ellens company to jointly promote the sales of 13C products in the Chinese market.

In May, the company established a new nuclear medicine center in Guangdong, Hunan, Yunnan and Sichuan by acquiring the equity of the nuclear medicine center subordinate to Guangdong Noble Group Co., Ltd.

In March, the company signed the strategic cooperation agreement with SDIC Juli Investment Management Co., Ltd. to speed up the strategic layout of nuclear drug industry and promote the long-term and high-speed development of the company.

In January, the company signed an intentional agreement with Japan's NMP company, and the two sides reached strategic cooperation intention on the R & D, application, production and operation of radioactive nuclear drugs.

 

 

  In 2018  


In September, the company shined the international conference stage of pharmaceutical innovation and development in 2018, and successfully held the professional forum of "precise treatment of tumor, innovation and application of radionuclide drugs". The company's deep cultivation and integration in the field of nuclear medicine attracted strong attention and response from the industry. The company signed a strategic cooperation agreement with the Institute of modern physics, Chinese Academy of Sciences, Based on the advantages of the Institute of modern physics in the development and production of accelerators, the production and separation of radioisotopes using accelerator technology and nuclear technology, as well as the advantages of Dongcheng pharmaceutical in nuclear drug qualification, nuclear drug network layout, nuclear drug research and development, clinical registration, drug production and marketing, the two sides jointly established new nuclides and nuclear drug innovation R & D companies and other forms to strengthen cooperation.

In September, the company successfully signed the framework cooperation agreement on investment in nuclear medicine with SDIC Juli Investment Management Co., Ltd. Relying on the strong financial support of SDIC, as well as its project operation experience and channel resources, Dongcheng will promote the company to better complete the industrial layout and integration in the field of nuclear medicine.

In August, the company and the Management Committee of Shanghai Fengcheng economic Park held a signing ceremony in Shanghai, and successfully signed the cooperation framework agreement between Shanghai Fengcheng economic Park and Dongcheng Pharmaceutical Group on the "Dongcheng nuclear medicine innovation and research industrial park project". The company plans to establish Dongcheng nuclear medicine innovation R & D Industrial Park in Shanghai. In the future, as the headquarters of Dongcheng nuclear medicine R & D and industrial base, it will build a domestic nuclear medicine innovation center integrating production, learning, research and clinical application, covering radioactive drug R & D and industrial base, foreign cooperation platform, nuclear medicine innovation incubator platform, etc.

 

 

  In 2017  

In December, the company increased capital and invested in China boron United Health to lay out the field of precision medicine for cancer.

In December, bailishu opened its sales door in Shanghai and became a domestic nadroparin calcium product that can be sold in the academic positions in Beijing, Shanghai and Guangzhou.

In October, the company completed the cash acquisition of 48.55% equity of Nanjing Jiangyuan Andico positron research and Development Co., Ltd.

In August, the Second Military Medical University and Zichen marine medicine jointly established the "Shanghai marine drug engineering technology research center".

In June, the company and 8 investors jointly established the nuclear medicine industry investment fund - Shanghai nuojai Xinkang investment management partnership.

In February, under the strategic cooperation with Shanghai Pharmaceutical in 2016, the cooperation with China Resources was completed in February, and the strategic cooperation with Sinopharm was completed in December.

In January, the company planned to acquire Nanjing Andico positron research and Development Co., Ltd. through this acquisition, the company will further improve the industrial layout of radioactive nuclear drugs, become a complete supplier of nuclear drugs and nuclear medicine solutions, and consolidate the company's position in the field of nuclear medicine.

 

 

  In 2016  

In August, The company invested 18.8 billion yuan in rhenium acid injection. The company invested 315 million yuan to control Thailand Sino Thai bio, realizing low-cost procurement of raw materials and global coordination

In March, The company successfully acquired Dongcheng Xinke, the founder of domestic diagnostic radionuclide preparations, with a total investment of 70 million US dollars, and completed the whole industrial chain layout of nuclear medicine from diagnosis to treatment

 

 

  2015  

In October, Chengdu Yunke Pharmaceutical Co., Ltd., a domestic manufacturer of radionuclide preparations for treatment, has invested 750 million yuan to control Chengdu Yunke Pharmaceutical Co., Ltd

 

 

  2014  

In June, The company officially changed its name to Yantai Dongcheng Pharmaceutical Group Co., Ltd., which marks that the company has basically completed the transformation from single product operation of API to the development of API and preparation and group development

 

 

  2013   

In September, The R & D and quality inspection building invested 85 million yuan by the company has been completed and put into use, equipped with international high-end scientific research equipment

In May, The company invested 167 million yuan to complete the acquisition of Yantai Dayang pharmaceutical

In March, The company invested 470 million yuan in the project "Dongcheng biomedical industrial park" officially started construction

 

 

  2012   

On May 25, Shenzhen Stock Exchange successfully listed

On May 14, Online Roadshow

In May, Roadshows in Shenzhen, Shanghai and Beijing

On May 3, Received the reply of CSRC on approval of Dongcheng IPO

On January 6, The listing application of Dongcheng Pharmaceutical Co., Ltd. passed the examination and approval of the national development and Examination Commission

 

 

  2008-2012   

Preparation work of Dongcheng Pharmaceutical Co., Ltd

On January 9, Dongcheng Pharmaceutical Group (formerly Dongcheng biochemical) Co., Ltd. officially opened

 

 

  2007   

On December 19, Dongcheng Pharmaceutical Group (formerly Dongcheng biochemical) Co., Ltd. was founded, and the listing work was officially launched

 

 

  2006   

Dongyuan Bioengineering Co., Ltd., a wholly-owned subsidiary, started construction in Yinan County, Shandong Province and completed the layout in the upstream of the industrial chain

 

 

  2002   

The company acquired Yantai North Pharmaceutical Co., Ltd., and the industrial chain extended to the downstream preparation industry

 

 

  Year 2000  

The company has become the first biochemical API enterprise which has passed the GMP certification of the State Food and drug administration

 

 

  1999   

The company was established and the first heparin sodium API was put into production

 

 

  1998   

Dongcheng Pharmaceutical (formerly known as Dongcheng biochemical) started construction, opening the prelude of rapid rise

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

contact us CONTACT US
0535-6391521
Switchboard: 86-535-6391521 / 6391522
Email: zxu @ midatlanticlegends.com
Address: No.7 Changbaishan Road, Yantai Development Zone, Shandong Province
Copyright 2014 Yantai Dongcheng Pharmaceutical Group Co., Ltd. All Rights Reserved Lu ICP Bei 18035060-1